Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Clinical trial NCT07125547 · RECRUITING

Trial details

NCT number: NCT07125547
Sponsor: Tianjin Medical University Second Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ureteral Cancer Neoadjuvant Therapy PD-1 Inhibitor Kidney-sparing Tislelizumab Nab-paclitaxel

Start date: 2025-07-05
Primary completion: 2026-12-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.